The 3 brilliant #ISGO25 scientific orals
1. Lauren McMahon @CancerInstIRE
2. Luna Stockmann @DCU
3. Donal Brennan @ucddublin
There is such an array of diverse & important scientific research in GYN cancer underway in 🇮🇪 . It's fantastic to see some projects at ISGO meeting 🥰
Dr Slamon the man whose research led to Herceptin. His work saves tens of thousands of women’s lives per year. Giving an open lecture @HerbertParkH Dublin Weds Sept 24 600pm. Free registration Karen.Culhane@ccrt.ie. Sponsored by @CCRTIreland@DCU
Check out @LunaStockmann’s amazing explanation of her research, why her research question is so important, and what she’s doing to help uncover kinder cancer treatments.
🔬 How do a sniffer dog and a detective inspire smarter, kinder cancer treatments?
@LunaStockmann's OvaLoad project is bringing us closer to new, better, smarter, kinder, and more effective ways to treat ovarian cancer.
🎥youtu.be/5pobUnQB404#MakeMoreSurvivors
Honoured to be invited to present my PhD Project "Enhancing Targeted Therapies for Triple Negative Breast Cancer" as a Lay-Poster in the Patrick G Johnston Session (5th of March 2025) at the Annual IACR Conference @News_IACR
So proud of @LunaStockmann! Grateful to @BreakthroCancer and @Researchirel for funding this important work on ovarian cancer treatments. Thanks to the PPI advocates and @OvaCare for helping Luna refine her presentation.
🥳🎉Celebrating Luna Stockmann - the 2025 Patrick Johnston Award winner for her amazing talk - OvaLoad: Enhanced Targeted Treatment for Ovarian Cancer. @News_IACR We especially loved you sniffer dog analogy 🐕 🦴
Proud to support this research with @Researchirel 👏👏
A new ADC is now available to treat the most common subtype of breast cancer.
Datopotamab deruxtecan (Dato-DXd), which targets Trop2 and delivers DXd, is approved for pretreated patients with HR /HER2- MBC, after outperforming chemo in the #TB01 trial.
fda.gov/drugs/resources-info…
Thank you to the Croatian Association for Cancer Research for inviting me to speak at HDIR-7 in Zagreb. Inspired by the impactful work to understand cancer from the molecular to the population level.
Meet #IUA3MT finalist @Niall_Ashfield representing DCU.
Niall is on a mission to improve treatments for HER2-positive breast cancer by studying the combined effects of two approved drugs and developing models to understand treatment resistance.
More info: iua.ie/3minutethesis
Huge thanks to colleagues across Ireland who came together for our Radiation Oncology translation research retreat 🙏
👉 Such energy positivity expertise and creativity as we form our ITROG constortoum 🙌
@IRROGTrials@irrsoc@IrishCancerSoc@cancertrials_ie@hseNCCP@HSELive
frontiersin.org/research-top…
The deadline is extended for submission to the @FrontiersIn Genetics special issue on “3D in Vitro Models - A New Era in Cancer Research”
Thanks go to @gerryhanna for organising this research retreat. It’s brilliant to have so many experts in radiation oncology across the island in one room. Thankful for the opportunity to present some of our work.